Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Viridian Therapeutics, Inc. - Common Stock
(NQ:
VRDN
)
16.13
+0.26 (+1.64%)
Streaming Delayed Price
Updated: 10:22 AM EDT, Jun 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viridian Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Top 3 Health Care Stocks You May Want To Dump This Quarter
↗
July 30, 2024
Via
Benzinga
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
July 25, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
↗
July 16, 2024
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine.
Via
Investor's Business Daily
Expert Ratings For Viridian Therapeutics
↗
July 16, 2024
Via
Benzinga
3 Small-Cap Stocks With Explosive 2X Growth Potential
↗
July 08, 2024
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024.
Via
InvestorPlace
7 Analysts Assess Viridian Therapeutics: What You Need To Know
↗
June 06, 2024
Via
Benzinga
Unveiling 4 Analyst Insights On Viridian Therapeutics
↗
March 20, 2024
Via
Benzinga
Navigating 6 Analyst Ratings For Viridian Therapeutics
↗
February 28, 2024
Via
Benzinga
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 03, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 11, 2024
Via
Benzinga
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
June 11, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
May 31, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
May 10, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
↗
May 08, 2024
VRDN stock results show that Viridian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
May 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
April 29, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
↗
March 19, 2024
Although cheap stocks under $20 represent a higher-risk profile, the rewards could be massive if the spotlight shines on them.
Via
InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 05, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
February 16, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
↗
January 18, 2024
Viridian Therapeutics shares are trading lower by 5.9% Thursday morning. The company announced pricing of an underwritten public offering.
Via
Benzinga
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
January 17, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 08, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Viridian Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
